HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
ID: 353592Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353592

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at advancing research to identify new pain targets within the understudied druggable proteome. This initiative invites applications for pilot projects under the R03 Small Grant Program, providing up to $100,000 for projects lasting one year, focused on generating preliminary data on specified understudied proteins relevant to pain management without involving clinical trials. This funding is critical in addressing the public health crisis related to opioid addiction and the need for effective pain management solutions, encouraging diverse participation and collaboration among researchers. Interested applicants must submit their proposals electronically by July 16, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-197-Full-Announcement.html
    PAR-24-197.html
    The Department of Health and Human Services is offering funding opportunities through the HEAL Initiative aimed at advancing research to identify new pain targets within the understudied druggable proteome. Specifically, this funding opportunity focuses on the R03 Small Grant Program, offering up to $100,000 for pilot projects lasting one year. Eligible institutions can apply to generate preliminary data on the role of specified understudied proteins in pain management without involving clinical trials. The initiative encourages diverse participation and collaboration among researchers while providing a platform to elucidate protein functions critical for developing novel pain therapies. Key proteins eligible for study have low prior research engagement, presenting significant potential for innovations in treating pain. Additionally, all funded projects must comply with rigorous data management and sharing requirements to maximize research impact. The application submission process will be conducted electronically, and proposals will be peer-reviewed for scientific merit, with a focus on their relevance, significance, innovation, and methodological approach. This opportunity is crucial in addressing the ongoing public health crisis related to opioid addiction and the need for effective pain management solutions.
    Similar Opportunities
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the HEAL Initiative: Pain Management Effectiveness Research Network, specifically for Clinical Trial Planning and Implementation through a Cooperative Agreement (UG3/UH3). This initiative aims to conduct large-scale, multisite clinical trials that will evaluate the efficacy of interventions designed to reduce opioid use and improve pain management across various conditions, thereby enhancing functional outcomes for patients suffering from acute to chronic pain. The program is critical in expanding evidence-based therapeutic options for pain relief, benefiting patients and their families. Interested applicants, including various eligible entities such as tribal governments and community organizations, are encouraged to prepare for this opportunity, with applications expected to be solicited starting October 15, 2025, and closing on January 5, 2026. For further inquiries, potential applicants can contact Dr. Yolanda F. Vallejo at 301-451-1751 or via email at Yolanda.Vallejo@nih.gov.
    HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Pain Research Enhancement Program (PREP), a federal grant aimed at supporting pain research projects from R15-eligible institutions. This initiative seeks to promote rigorous basic and mechanistic pain research, foster interdisciplinary collaborations, and enhance the research environment for health professional trainees and students. The program is crucial for diversifying the pain research workforce and advancing understanding of pain mechanisms, with funding available up to $375,000 over a maximum three-year period. Applications will be accepted starting October 18, 2024, with a deadline of November 19, 2024, and interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Pain Research Enhancement Program (PREP), a federal grant aimed at supporting rigorous basic and mechanistic pain research at R15-eligible institutions. This initiative seeks to foster interdisciplinary partnerships between eligible Principal Investigators (PIs) and other U.S. domestic entities, while enhancing the research environment for health professional trainees and students through active engagement in pain research projects. Grants of up to $375,000 are available for a maximum duration of three years, with applications due by 5:00 PM local time on November 23, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage for more details.
    Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.
    HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems." This initiative aims to develop strategies to enhance the sustainable and effective delivery of integrated care for individuals suffering from both chronic pain and OUD, addressing barriers at the health systems level. The importance of this opportunity lies in its focus on improving collaborative care models and implementation strategies to better manage these co-occurring conditions, which affect a significant portion of the population. Interested applicants, particularly small businesses with expertise in chronic pain management and OUD, are encouraged to prepare for the application process, with the estimated synopsis post date set for January 12, 2026, and the estimated award date anticipated for April 1, 2027. For further inquiries, potential applicants can contact Shelley Su, Ph.D., at IMPOWR@nih.gov or by phone at 301-402-3869.
    Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Network (ERN) (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Network (ERN) (Clinical Trial Not Allowed)." This initiative aims to renew the HEAL Pain Management Effectiveness Research Network Resource Centers, which are essential for planning, implementing, and completing large-scale multisite clinical trials focused on effective pain management strategies across various diseases and conditions. The Resource Centers will provide operational expertise, clinical coordination, data management, and recruitment support to enhance pain management research. Interested applicants must be recipients of RFA-TR-22-012, with applications peer-reviewed for merit. The estimated award date is August 2, 2027, and the project is expected to commence on September 2, 2027. For further inquiries, contact Yolanda F. Vallejo, PhD, at yolanda.vallejo@nih.gov or call 301-451-1751.